AHA 2020 | Omega-3 Fatty Acids Provide No Cardiovascular Benefits and Cause More Atrial Fibrillation

Results confirm the interim analysis, whereby the study was suspended for futility. Omega-3 fatty acids do not reduce cardiovascular events in patients with high triglycerides and low HDL.

Previous studies, such as REDUCE-IT, had shown positive results, but given this new research (presented at the American Heart Association [AHA] 2020 Congress and simultaneously published in JAMA), we need to come to terms with the fact that omega-3 fatty acids provide no benefit.

The problem in REDUCE-IT was that the control arm received mineral oil. That has a pro-inflammatory effect: it increases LDL, apolipoprotein B, and C reactive protein. All of that supported the interpretation that the differences between treatment arms were linked to the benefit derived from omega 3 acids, when they were probably due to the adverse events in the control group.

However, in the STRENGTH study, the control arm used corn oil, which has a neutral effect.

The study included 13,078 patients under statin treatment, presenting high risk for cardiovascular events, with high triglycerides (180 to 500 mg/dl), and low HDL (<42 mg/dl in males and <47 mg/dl in women).


Read also: AHA 2020 | RIVER: Rivaroxaban as Alternative to Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Mitral Valve.


Participants were randomized to corn oil or omega 3 fatty acids (such as eicosapentaenoic acid and docosahexaenoic acid).

At a mean 42 months of follow-up, omega 3 fatty acids did not reduce cardiovascular death, infarction, coronary revascularization, or hospitalization for unstable angina (12.0% vs. 12.2%; hazard ratio [HR]: 0.99; 95% confidence interval [CI]: 0.90-1.09).

There was an increased risk for new atrial fibrillation (2.2% vs. 1.3%; HR: 1.69; 95% CI: 1.29-2.21) with omega 3, which is consistent with the results of REDUCE-IT.

STRENGTH

Original Title: Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial.

Reference: Nicholls SJ et al. JAMA. 2020; Epub ahead of print y presentado en el congreso AHA 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....